Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism
Churaibhon Wisessaowapak, Yuliya Skorobogatko, Hyeonhui Kim, Xue Feng, Seunghwan Son, Haipeng Fu, Sitao Zhang, Pichaya Lertvilai, Lina Chang, Annie Hoang, Hetty Chen, Sarah Bedsted, Joseph Valentine, Jin Young Huh, Peng Zhao, Shannon M. Reilly, Piyajit Watcharasit, Maryam Ahmadian, Alan R. Saltiel
Churaibhon Wisessaowapak, Yuliya Skorobogatko, Hyeonhui Kim, Xue Feng, Seunghwan Son, Haipeng Fu, Sitao Zhang, Pichaya Lertvilai, Lina Chang, Annie Hoang, Hetty Chen, Sarah Bedsted, Joseph Valentine, Jin Young Huh, Peng Zhao, Shannon M. Reilly, Piyajit Watcharasit, Maryam Ahmadian, Alan R. Saltiel
View: Text | PDF
Research Article Endocrinology Metabolism

A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism

  • Text
  • PDF
Abstract

Metabolic adaptation to both caloric excess and restriction promotes energy conservation by suppressing catabolic pathways via feedback mechanisms that remain incompletely defined. We identified TANK binding kinase 1 (TBK1) as a nutrient- and inflammation-responsive brake on AMPK signaling in adipocytes. Fasting or pharmacological AMPK activation induced Tbk1 transcription via a PGC1α/nuclear respiratory factor 1 axis, which, in turn, limited AMPK activity through a phosphorylation cascade to conserve energy. In obesity, this AMPK/TBK1 axis was disrupted due to chronically elevated basal TBK1, thereby restricting energy expenditure during fasting. Adipocyte-specific TBK1 deletion enhanced fasting-induced AMPK activation, mitochondrial function, and lipolytic gene expression in both lean and obese mice. Pharmacological TBK1 inhibition with amlexanox recapitulated these effects. Combined treatment of mice with amlexanox and the AMPK activator AICAR enhanced weight loss, improved glucose tolerance and insulin sensitivity, and suppressed inflammatory and lipogenic programs in adipose tissue, as well as fibrotic gene expression in the liver. Building on prior clinical observations linking TBK1 inhibition to metabolic health, these findings defined a nutrient-sensitive AMPK/TBK1 feedback loop that limited adipocyte catabolism and suggested that dual targeting of TBK1 and AMPK may help counteract metabolic adaptation and enhance the durability of obesity therapies.

Authors

Churaibhon Wisessaowapak, Yuliya Skorobogatko, Hyeonhui Kim, Xue Feng, Seunghwan Son, Haipeng Fu, Sitao Zhang, Pichaya Lertvilai, Lina Chang, Annie Hoang, Hetty Chen, Sarah Bedsted, Joseph Valentine, Jin Young Huh, Peng Zhao, Shannon M. Reilly, Piyajit Watcharasit, Maryam Ahmadian, Alan R. Saltiel

×

Figure 2

Fasting induces Tbk1 in adipose tissue through AMPK.

Options: View larger image (or click on image) Download as PowerPoint
Fasting induces Tbk1 in adipose tissue through AMPK.
(A) qPCR analysis o...
(A) qPCR analysis of Tbk1 and Ppargc1a mRNA in iWAT from ND mice treated with 500 mg/kg AICAR (i.p.) for 0, 3, 6, or 24 hours. n = 2–3, 1-way ANOVA with Tukey’s multiple-comparison test. (B) Immunoblot analysis of iWAT from ND mice treated with 500 mg/kg AICAR (i.p.) for 0.5, 1, or 3 hours, probed for pS79 ACC, ACC, pT172 AMPK, AMPK, pS172 TBK1, TBK1, and HSP90. (C and D) Differentiated 3T3-L1 adipocytes were pretreated with 10 μM Compound C for 30 minutes followed by 10 μM PF-739 or 500 μM AICAR for 6 hours. qPCR analysis of Tbk1 and Ppargc1a (C) and quantification of pT172 AMPK/AMPK and TBK1/HSP90 (D) are shown. n = 3, 2-way ANOVA with Tukey’s multiple-comparison test. (E) Differentiated 3T3-L1 adipocytes were transfected with siRNA targeting AMPKα1 and α2 for 3 days, then stimulated with 10 μM PF-739 for 6 hours. qPCR analysis of Tbk1 and Ppargc1a is shown. n = 3, 2-way ANOVA with Tukey’s multiple-comparison test. (F) iWAT from Prkaa1/2AKO (AAKO) mice fasted for 48 hours was analyzed for Tbk1 and Pnpla2 mRNA expression. n = 3–4, 1-way ANOVA with Tukey’s multiple-comparison test. Data are presented as mean ± SEM; each dot represents a biological replicate. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts